Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial
- PMID: 18502028
- DOI: 10.1016/j.eururo.2008.04.062
Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial
Abstract
Background: Until now no confirmatory clinical trial in children suffering from nonneurogenic overactive bladder (OAB) and urinary incontinence could demonstrate superiority for antimuscarinics over placebo.
Objectives: The following study was conducted to prove efficacy and tolerability of propiverine compared to placebo.
Design, setting, and participants: A randomized, double-blind, placebo-controlled phase 3 trial with parallel-group design in children aged 5-10 yr was performed. Prior to the 8-wk medical therapy urologic baseline diagnostics, a 3-wk lifestyle advice (urotherapy) was established.
Intervention: After re-evaluation of in- and exclusion criteria and uroflowmetry, only children fulfilling the requested criteria were allocated to a body-weight-adjusted therapy (10 or 15 mg propiverine twice daily or corresponding placebo).
Measurements: Efficacy parameters derived from bladder diary and a micturition volume protocol. Decrease in voiding frequency per day was chosen as primary efficacy parameter; secondary endpoints included voided volume and incontinence episodes. A safety assessment was conducted.
Results and limitations: Of 171 randomized children, 87 were treated with propiverine and 84 with placebo. The primary efficacy parameter showed a decrease in voiding frequency (-2.0 episodes for propiverine versus -1.2 for placebo; p=0.0007). Superiority could also be demonstrated for voided volume (31.4 vs. 5.1 ml; p<0.0001) and incontinence episodes (-0.5 vs. -0.2 episodes per d; p=0.0005). The trial design did not allow for separate evaluation of the effect of urotherapy prior to medical treatment. Propiverine was well-tolerated in children. Altogether 23% of side-effects were reported for propiverine and 20% for placebo.
Conclusions: This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence. An important additional factor for the success of the trial was a modified trial design with previous urotherapy.
Trial registration: ClinicalTrials.gov Identifier: NCT00603343.
Comment in
-
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.Eur Urol. 2009 Mar;55(3):737. doi: 10.1016/j.eururo.2008.04.063. Epub 2008 May 7. Eur Urol. 2009. PMID: 18502023 No abstract available.
-
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.Eur Urol. 2009 Mar;55(3):737-8. doi: 10.1016/j.eururo.2008.04.064. Epub 2008 May 7. Eur Urol. 2009. PMID: 18502027 No abstract available.
-
Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009;55:729-38.Eur Urol. 2009 Jul;56(1):e1; author reply e2. doi: 10.1016/j.eururo.2008.11.029. Epub 2008 Nov 25. Eur Urol. 2009. PMID: 19056165 No abstract available.
Similar articles
-
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.BJU Int. 2007 Sep;100(3):579-87. doi: 10.1111/j.1464-410X.2007.07031.x. BJU Int. 2007. PMID: 17669143 Clinical Trial.
-
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.Eur Urol. 2009 Mar;55(3):737-8. doi: 10.1016/j.eururo.2008.04.064. Epub 2008 May 7. Eur Urol. 2009. PMID: 18502027 No abstract available.
-
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.Int J Urol. 2009 May;16(5):499-506. doi: 10.1111/j.1442-2042.2009.02286.x. Epub 2009 Mar 29. Int J Urol. 2009. PMID: 19389083 Clinical Trial.
-
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.Eur Urol. 2004 Apr;45(4):420-9; discussion 429. doi: 10.1016/j.eururo.2004.01.008. Eur Urol. 2004. PMID: 15041104 Review.
-
The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms.Eur Urol. 2006 Sep;50(3):440-52; discussion 453. doi: 10.1016/j.eururo.2006.05.014. Epub 2006 May 19. Eur Urol. 2006. PMID: 16753253 Review.
Cited by 20 articles
-
Canadian Urological Association guideline for the treatment of bladder dysfunction in children.Can Urol Assoc J. 2021 Feb;15(2):13-18. doi: 10.5489/cuaj.6975. Can Urol Assoc J. 2021. PMID: 33007188 Free PMC article. No abstract available.
-
EAU-ESPU guidelines recommendations for daytime lower urinary tract conditions in children.Eur J Pediatr. 2020 Jul;179(7):1069-1077. doi: 10.1007/s00431-020-03681-w. Eur J Pediatr. 2020. PMID: 32472266
-
Comparative assessment of efficacy and safety of different treatment for de novo overactive bladder children: A systematic review and network meta-analysis.Asian J Urol. 2019 Oct;6(4):330-338. doi: 10.1016/j.ajur.2019.04.001. Epub 2019 Apr 13. Asian J Urol. 2019. PMID: 31768318 Free PMC article.
-
Conservative interventions for treating functional daytime urinary incontinence in children.Cochrane Database Syst Rev. 2019 Sep 18;9(9):CD012367. doi: 10.1002/14651858.CD012367.pub2. Cochrane Database Syst Rev. 2019. PMID: 31532563 Free PMC article.
-
Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis.Int Urol Nephrol. 2019 Sep;51(9):1459-1471. doi: 10.1007/s11255-019-02209-y. Epub 2019 Jun 26. Int Urol Nephrol. 2019. PMID: 31243632
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
